banner
darknatter.bsky.social
Paul Dark
@darknatter.bsky.social
690 followers 330 following 23 posts
Healthcare professional, educator and researcher, Manchester, UK https://research.manchester.ac.uk/en/persons/paul.m.dark 🇬🇧 🇨🇭
research.manchester.ac.uk
Posts Media Videos Starter Packs
Reposted by Paul Dark
sepsisresearch.bsky.social
Sepsis Research FEAT @sepsisresearch.bsky.social · Jul 3
As @ics-updates.bsky.social updates #SOA25 congress draws to a close in Birmingham, Professor Paul Dark @darknatter.bsky.social of manchester.ac.uk emphasises the importance of this charity’s priority setting exercise in ensuring that patient needs are addressed by future sepsis research programmes
1 2 6
Reposted by Paul Dark
andymoz78.bsky.social
Andy Conway Morris @andymoz78.bsky.social · Jun 6
New from @jomcpeake.bsky.social @iculone.bsky.social @darknatter.bsky.social and colleagues from @sepsisresearch.bsky.social the full publication of the Sepsis Research priorities.
These set out the research priorities from established sepsis survivors, families, carers and healthcare professionals
Top 10 research priorities for sepsis research determined by patients, carers and clinicians
Introduction Sepsis is a high burden syndrome associated with increased morbidity and mortality in both the acute and longer-term phases of illness. Multiple treatment uncertainties remain that requ.....
doi.org
1 7 13
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · May 20
We believe there is no such thing as a negative result - JAMA Editors agree, thankfully 👏
1 1
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · May 19
More resesrch results from UK critical care 👏
jama.com
JAMA @jama.com · May 19
In critically ill patients, neither dexmedetomidine nor clonidine was superior to propofol in reducing time to successful extubation. #ATS2025

https://ja.ma/3Sw1K4Z
Figure 2. Cumulative Incidence Plot for Time From Randomization to Successful Extubation
1 3 4
Reposted by Paul Dark
benmorton.bsky.social
Ben Morton @benmorton.bsky.social · Apr 1
Please consider responding to this important survey following on from publication of the ADAPT-Sepsis trial

jamanetwork.com/journals/jam...

#IDsky #Medsky #ICUsky #Ansky 🧪
3 2
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Apr 1
Have your say - an invitation to complete this important survey to inform UK implementation sespsis patient care research in PCT-guided antibiotic duration. www.qualtrics.manchester.ac.uk/jfe/preview/... @benmorton.bsky.social @ics-updates.bsky.social @criticalcarereviews.com
Preview - Qualtrics Survey | Qualtrics Experience Management
The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.
www.qualtrics.manchester.ac.uk
1 7 8
Reposted by Paul Dark
jama.com
JAMA @jama.com · Feb 25
Editor’s choice from the February 25 issue.

➡️ Camrelizumab With Chemotherapy in Patients With Early or Locally Advanced TNBC
➡️ Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis
➡️ Essential Thrombocythemia: A Review; and more.

ja.ma/4hR14SI

#JAMA #MedSky
1 2 7
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Jan 27
@davidaharrison.bsky.social ?
1 3
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Jan 24
www.thebottomline.org.uk/summaries/ad...
ADAPT-Sepsis: PCT or CRP Guided Antibiotic Duration
ADAPT-Sepsis: PCT or CRP-guided Antibiotic Duration for Patients with suspected Sepsis Dark et al. JAMA Dec 9 2024. doi:10.1001/jama.2024.26458 Clinical Question For critically ill adults with suspect...
www.thebottomline.org.uk
1 6 11
Reposted by Paul Dark
criticalcarereviews.com
Critical Care Reviews @criticalcarereviews.com · Jan 10
The third trial result for #CCR25 in Titanic Belfast in June is the UK-Rox Trial

Evaluating the clinical & cost-effectiveness of a conservative approach to oxygen therapy for invasively ventilated adults in ICU

Register via the QR code or on the CCR website
criticalcarereviews.com/meetings/ccr25
9 18
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Jan 1
Aim for 2025
6
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 25
Schöni Wiehnachte 🇨🇭 🎄 ♥️ ❄️
1 7
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 13
Detailed trial process evaluation coming soon - at least what was possible during the complexity of an unexpected global pandemic and the aftershock.
1 4
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 13
Kathy announced it day 2 - good move!
2
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 11
Thanks - I had dark hair at the start of this!
2
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 11
This is the very first part of a programme. You're will hear more about our trial process evaluation and health economic analysis early in 2025 - then a good go at bringing our data into the pool of open label trial results - remember our work also included intervention concealment.
1 1
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 11
Thanks Nick. Our motivation was to address a tight brief from the public funded, government run UK research sector, with mandated 3 arm rct including standard care and one of each, daily pct or crp discontinuation protocols. We wanted to add more quality to the evidence and, of course, MA in time.
1 1 2
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 11
Thanks Ben, explanation - data linkage with NHS was a nightmare, got this from our team on the way to the conference - you couldn't make it up. We'll find a way to disseminate somehow - but the 90-all cause is in the secondary outcomes.
1 5
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 11
@criticalcarereviews.com
Congratulations to the newly announced PROFESSOR Rob MacSweeney. Richly deserved for a modest person who works tirelessly in support of improving care of the critically ill through world leadership and creativity for clinical research dissemination with real impact. 👏 Prof.
4 10 52
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 10
... and also meet our funder's pre-specified brief of testing two biomarker protocols in a 3 arm rct.
3
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 10
Agree Lars, it's going to be how we get to understand all of this to progress care. I would also say that there are a number of open label pct trials out there that will need to be considered as a body of work - our trial was an attempt to add to knowledge with an intervention concealment strategy
1 2 4
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 10
Due to persistent challenges with data linkage for trials in the UK, we didn't get this KM plot into the final online manuscript, but we were able to show @CCR Down Under yesterday . The end of the 90-day follow-up was in September 2024.
3 5
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 10
See above Jack
3
darknatter.bsky.social
Paul Dark @darknatter.bsky.social · Dec 10
It's a superiority trial with sample size estimate to detect a 1 day reduction in total antibiotic duration to day 28 for intervention(s) vs control. We were able to monitor safety (28-day all cause mortality)for this sample size with the stated NI margin. + 90-day all cause mortality was reported.
1 2 6
Reposted by Paul Dark
criticalcarereviews.com
Critical Care Reviews @criticalcarereviews.com · Dec 10
Chief Investigator @darknatter.bsky.social shares insights from the #ADAPTsepsistrial at #CCRdownunder

@adaptsepsis @jama.com
7 18